Journal
ADVANCED HEALTHCARE MATERIALS
Volume 10, Issue 21, Pages -Publisher
WILEY
DOI: 10.1002/adhm.202100683
Keywords
ferritin; ferritinophagy; ferroptosis; sorafenib; tumor immunity
Funding
- National Natural Science Foundation of China [81972812]
- Shanghai Jiao Tong University Starting Program for Young New Teachers [20x100040060]
Ask authors/readers for more resources
The combination therapy utilizing ferritinophagy-cascade ferroptosis and tumor immunity activation shows promise for cancer treatment. The use of active tumor targeting nanoparticles to release drugs for inhibiting tumor growth and metastasis is an effective strategy.
Ferritin internalized into tumor cells is degraded and releases iron ions via ferritinophagy. Iron ions participate in Fenton reaction to produce reactive oxygen species for lipid peroxidation and ferroptosis. Inhibition of indoleamine-2,3-dioxygenase (IDO) decreases tryptophan elimination to induce T cells activation for tumor immunosuppression relief. The active tumor targeting nanoparticles containing ferritin and a pH-sensitive molecular-switch (FPBC@SN) are developed to utilize ferritinophagy-cascade ferroptosis and tumor immunity activation for cancer therapy. FPBC@SN disintegrates in acidic cytoplasm and releases sorafenib (SRF) and IDO inhibitor (NLG919). SRF upregulates nuclear receptor coactivator 4 (NCOA4) to induce ferritin and endogenous iron pool degradation by ferritinophagy, then obtained iron ions participate in the Fenton reaction to produce lipid peroxide (LPO). Meanwhile, SRF blocks glutathione synthesis to downregulate glutathione peroxidase 4 (GPX4) which can scavenge LPO as a different pathway from ferritinophagy to promote ferroptosis in tumor cells. NLG919 inhibits IDO to reduce tryptophan metabolism, so immunity in tumors is aroused to anti-tumor. In vitro and in vivo experiments prove FPBC@SN inhibits tumor cell growth and metastasis, indicating the potential of FPBC@SN for breast cancer therapy based on the combination of ferritinophagy-cascade ferroptosis and tumor immunity activation.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available